Phenotypic, genomic and functional characterization reveals no differences between CD138++ and CD138low subpopulations in multiple myeloma cell lines.

por Teresa Paíno, María E Sarasquete, Bruno Paiva, Patryk Krzeminski, Laura San-Segundo, Luis A Corchete, Alba Redondo, Mercedes Garayoa, Ramón García-Sanz, Norma C Gutiérrez, Enrique M Ocio, Jesús F San-Miguel
Publicado 2014

Dasatinib as a bone-modifying agent: anabolic and anti-resorptive effects.

por Antonio Garcia-Gomez, Enrique M Ocio, Edvan Crusoe, Carlos Santamaria, Pilar Hernández-Campo, Juan F Blanco, Fermin M Sanchez-Guijo, Teresa Hernández-Iglesias, Jesús G Briñón, Rosa M Fisac-Herrero, Francis Y Lee, Atanasio Pandiella, Jesús F San Miguel, Mercedes Garayoa
Publicado 2012

Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone disease

por Antonio Garcia-Gomez, Tianlu Li, Carlos de la Calle-Fabregat, Javier Rodríguez-Ubreva, Laura Ciudad, Francesc Català-Moll, Gerard Godoy-Tena, Montserrat Martín-Sánchez, Laura San-Segundo, Sandra Muntión, Xabier Morales, Carlos Ortiz-de-Solórzano, Julen Oyarzabal, Edurne San José-Enériz, Manel Esteller, Xabier Agirre, Felipe Prosper, Mercedes Garayoa, Esteban Ballestar
Publicado 2021